inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.

被引：0

作者：

Sehn, Laurie Helen

Hubel, Kai

Luminari, Stefano

Salar, Antonio

Wahlin, Bjorn E.

Gopal, Ajay K.

Bonnet, Christophe Marc

Paneesha, Shankara

Trneny, Marek

Mashegu, Hafsat Umar

Lihou, Christine Francis

Li, Di

Scholz, Christian W.

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Hosp Cologne, Dept Internal Med Oncol & Hematol 1, Cologne, Germany

[4] Azienda USL IRCCS Reggio Emilia, Hematol Unit, Reggio Emilia, Italy

[5] Hosp Mar IMIM, Dept Haematol, Barcelona, Spain

[6] Karolinska Inst, Unit Hematol, Dept Med, Stockholm, Sweden

[7] Univ Washington, Div Med Oncol, Seattle, WA USA

[8] Univ Liege, Clin Hematol, Ctr Hosp Univ, Liege, Belgium

[9] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[10] Charles Univ Hosp, Prague, Czech Republic

[11] Incyte Corp, Wilmington, DE USA

[12] Vivantes Klinikum Urban, Dept Hematol & Oncol, Berlin, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7583

引用

页数：1